MTOR and diffuse large B-cell lymphoma: Using this random signature approach, there were additional new findings: for example, signatures of Core reactive, TSC/mTOR and Hormone receptor pathways were selected for a rare cancer, Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (DLBC), that were not found by the FDR-adjustment (Supplementary Fig. S21 and Supplementary Table S8).